EGFR and non-small cell lung carcinoma: Several major lung cancer treatment guidelines recommend that lung cancer patients be screened for EGFR mutations and advanced NSCLC patients harbouring EGFR-sensitive mutations be given first line TKI therapy whereas patients with negative or unknown EGFR mutation status be given platinum-based regimens13, 14.